Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (361)	2/3/1999 1:26:00 AM
From: aknahow	Read Replies (1) \| Respond to of 712

I don't know. I repeat that I think that CORR sandbagged the targets. When CORR talked about weekly sales being $750,000 it is now obvious they knew that was the average of 12 weeks, rather than sales during the last week as was reported. I don't like this sort of B.S. either. I think that the post on this thread have been of great value. I "know" one of the posters from another thread and believe his post on usage where he works are 100% accurate. Even sandbagging by CORR is of value. Since sales during the 12 weeks averaged $750,000 we know that the first of these weeks was not close to $750,000 and that another posters suggestion that they were around $1,400,000 ??? per week at the end, probably are correct. With no further ramping that would be about $17 million in this quarter. I would bet on $20 million but for the rest of the year I would prefer to be wrong just on this quarter.<g> If the sales are above $20 million I will become very bullish on this stock but still concerned about the cost of future trials.